Although literature suggests that approximately 5-10% of multifocal breast cancer patients exhibit HER2 heterogeneity across different lesions (41–43), the multifocal cases in this study were limited and demonstrated consistent HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.